Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.


NDAQ:PULM - Post by User

Pulmatrix Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(231)
•••
Post by whytestockson Aug 13, 2024 1:02pm
440 Views
Post# 36176832

Pulmatrix Announces Second Quarter 2024 Financial Results an

Pulmatrix Announces Second Quarter 2024 Financial Results an
JUST IN: $PULM Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate UpdatePulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Completed series of transactions with MannKind Corporation validating iSPERSE &#x2122; technology and extending projected cash runway into Q4 2026 $12.4 million ...PULM - Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities